RESEARCH AND EDUCATION DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Enicepatide, also identified as CT-388 and RO7795068, is an experimental compound studied for activity at both GLP-1 and GIP receptors. The evidence includes a peer-reviewed preclinical and phase 1 report, a 48-week phase 2 conference abstract, and registered clinical studies. These sources answer different questions and should be labeled accordingly. Findings from the clinical development program do not validate a separately supplied research material or establish its suitability for personal use. [1–3]
WHAT IS ENICEPATIDE?
Enicepatide is a single peptide-based compound designed to activate two receptors involved in metabolic signaling: the glucagon-like peptide-1 receptor and the glucose-dependent insulinotropic polypeptide receptor. These are commonly abbreviated GLP-1R and GIPR. [1]
The phase 2 trial record identifies enicepatide by the CT-388 development code. Matching these names helps readers find the relevant studies without confusing the compound with other dual-receptor agonists. Similar receptor targets do not make different molecules equivalent. [3]
WHAT DOES SIGNAL-BIASED MEAN?
The discovery report describes CT-388 as favoring signaling through cyclic AMP, a messenger inside cells. In laboratory assays, it activated both receptors with relatively little receptor internalization compared with their natural ligands. Internalization refers to movement of receptors from the cell surface into the cell. [1]
This describes experimental pharmacology. It does not, by itself, establish that a compound is more effective, better tolerated, or longer lasting in people than every alternative. Clinical outcomes require clinical comparisons.
WHAT DID THE EARLY HUMAN STUDY REPORT?
A peer-reviewed report combined animal experiments with a randomized, blinded, placebo-controlled phase 1 study. After four weeks, mean body-weight change across the CT-388 groups ranged from a reduction of 4.7% to 8.0%, versus 0.5% with placebo. Glucose measurements also changed, and most reported adverse events were mild or moderate. [1]
Four weeks is a short observation period. Early changes cannot establish long-term maintenance, uncommon risks, or outcomes after treatment stops. Animal findings reported in the same paper also need to remain distinct from the human results.
WHAT DID THE PHASE 2 CONFERENCE REPORT ADD?
A 2026 American Diabetes Association conference abstract described a randomized, blinded, placebo-controlled trial in 467 adults with overweight or obesity and without type 2 diabetes. The study followed participants for 48 weeks and evaluated several active groups. [2]
The abstract reported estimated body-weight reduction of up to 22.7% using an efficacy analysis. Gastrointestinal events were the most frequent adverse events, and the authors reported low rates of discontinuation because of adverse events. [2]
This is a conference abstract, which provides less methodological and safety detail than a complete trial report. The result should be identified by its study population, time point, and analysis rather than presented as a guaranteed outcome. It also does not establish superiority over another compound tested in a different trial.
WHAT DOES A TRIAL REGISTRATION TELL US?
The registry entry for NCT06525935 documents the phase 2 study's identity and planned design. A separate registered phase 2 study, NCT06628362, addresses participants with overweight or obesity and type 2 diabetes. [3,4]
A trial record describes what investigators intend to test and may provide updates or results. Registration alone is not evidence that an intervention worked. Results in people without diabetes should not be silently transferred to a diabetes population merely because another study has been registered.
WHAT REMAINS UNCERTAIN?
The reviewed evidence supports further investigation of metabolic outcomes. It does not answer every question about long-term safety, durability, cardiovascular events, or effects in populations not represented by the studies. Strong early results still need interpretation in the context of the full trial program.
For laboratory research, the compound's documented identity and the intended experiment remain central. A study of a controlled clinical formulation cannot verify the purity, stability, or biological activity of a different preparation. Research summaries should explain the science without turning clinical-development findings into instructions for use of a research product.
REFERENCES
Study titles below are shortened for readability; each link identifies the original publication or trial record.
[1] Chakravarthy MV, Rodriguez R, Hergarden A, et al. CT-388, a signaling-biased GLP-1/GIP receptor agonist: Preclinical and phase 1 findings. Molecular Metabolism. 2026;103:102291.
https://doi.org/10.1016/j.molmet.2025.102291
[2] Lingvay I, et al. CT-388 in overweight or obesity: A 48-week phase 2 study. Conference abstract 2813-LB. Diabetes. 2026;75(Supplement 1).
https://doi.org/10.2337/db26-2813-LB
[3] ClinicalTrials.gov. NCT06525935: Enicepatide (CT-388) in obesity or overweight with a weight-related comorbidity. Trial registration.
https://clinicaltrials.gov/study/NCT06525935
[4] Roche ForPatients. NCT06628362: Enicepatide (CT-388) in overweight or obesity with type 2 diabetes. Trial description.
https://forpatients.roche.com/en/trials/metabolic-disorder/obesity/a-study-of-ct-388-in-participants-who-are-overweight-or-91515.html